Raven Reports Results of RAV12 Study

November 20, 2007

Raven Biotechnologies released updated results from an ongoing Phase I/IIa open-label, dose-escalation trial of RAV12, its lead therapeutic antibody in development for the treatment of adenocarcinomas.

The trial began in December 2004 in patients with recurrent adenocarcinoma who had received one to three treatment courses. RAV12 was administered four times weekly, then by fractionated dosing two or three times weekly.

One patient with refractory colorectal cancer experienced a partial remission with time to progression exceeding eight months, and one patient with advanced pancreatic cancer had a greater than 50 percent reduction in the relevant tumor marker CA19-9 and experienced disease stability for more than five months.

As a result of these findings, future development of RAV12 both as a single agent and in combination with chemotherapy is planned for 2008, Raven said.